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Most of the locally advanced and metastatic prostate carcinomas (PCs) treated with antiandrogenic therapy
eventually become refractory to this treatment. Locally produced factors may control prostate tumor biology after
androgen withdrawal. Adrenomedullin (AM) is expressed in the prostate and could control cell growth in androgen-
independent conditions. AM needs to be amidated by the enzyme peptidylglycine a-amidating monooxygenase (PAM)
to become fully active. The objective of the present study was to analyze whether the expression of preproa-
drenomedullin (preproAM) and PAM in PC is regulated by androgens. For this purpose, human in vitro and in vivo PC
models were grown in the presence or absence of androgens, and the expression of AM and PAM was examined by
immunohistochemistry, Western blotting, RT-PCR, and Northern blotting. Furthermore, immunohistochemical analysis
of AM in clinical specimens was performed to test if its expression is related to Gleason score and antiandrogenic
therapy. In PC cell lines and xenografts, mRNA and protein AM levels were similar in the presence or absence of
androgens. PAM expression seemed to be induced by androgen-withdrawal. Our results in clinical samples showed no
relationship between AM expression and Gleason score or antiandrogenic treatment. In conclusion, our results
demonstrate that preproAM and PAM expression in the human prostate is androgen-independent. In addition, we
also report for the first time the expression of a novel PAM transcript in PC, which has not been previously described in
other tissues.  2003 Wiley-Liss, Inc.
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INTRODUCTION
Prostate growth, differentiation, andmaintenance
strongly depend on the presence of androgens
[1]. Since prostatic neoplastic cells are initially
responsive to androgens, conventional treatment
for advanced and disseminated prostate carcinoma
(PC) includes androgenic suppression. However,
many tumors become refractory to this treatment,
which implies a very poor prognosis for the patient
[2]. In the prostate, factors that are locally produced
contribute to its homeostatic control. Prostate epi-
thelial secretory cells and fibroblasts produce several
growth factors (GFs) [3], and neuroendocrine
cells synthesize diverse neuropeptides [4]. Some
studies suggest that someof theseGFs andneuropep-
tides can regulate prostatic epithelial cell growth in
the absence of androgens [5,6]. Some local GFs and
epithelial cell receptors suffer dramatic changes in
expression after androgen removal [3]. The study of
these factors becomes critical, because they could
favor prostate cancer tumor regrowth under andro-
gen-free conditions.
ProadrenomedullinN-terminal 20 peptide (PAMP)
and adrenomedullin (AM) are regulatory peptides
originating from the post-translational processing
of preproadrenomedullin (preproAM) precursor [7].
AM is a pluripotent peptide that has been related
to cell growth control [8,9]. AM and other GFs and
neuropeptides expressed by prostatic cells require
post-translational amidation to be completely bio-
active [10,11]. COOH–terminal a-amidation is
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sequentially performed by two enzymatic activities
included in peptidylglycine a-amidating mono-
oxygenase (PAM): peptidylglycine a-hydroxilating
monooxygenase (PHM) and peptidyl-a-hydroxygly-
cine a-amidating lyase (PAL) [12].
PAMP has been found in neuroendocrine cells of
normal andmalignant prostate [13,14].On the other
hand, normal and neoplastic nonneuroendocrine
epithelial cells showAM-immunoreactivity [13–15].
The amidating enzyme PAM is mainly produced by
normal and malignant neuroendocrine cells and, to
a lesser extent, by tumor cells [13–15]. Rocchi et al.
[15] showed thatAMslightly promotes cell growth in
DU-145 cells. However, we have recently shown
that overexpression of the preproAM gene in PC-3
cells results in a significant decrease in cell growth
rates [16].
In the present work, we have used human PC
experimental models (xenografts and cell lines) to
study whether the expression of AM and PAM is
altered by androgen deprivation. We have also
analyzed whether AM expression changes in rela-
tionship to tumor grade or antiandrogenic therapy
in clinical PCs.
MATERIALS AND METHODS
Prostatic Clinical Specimens
Normal prostates (n¼ 2) were obtained from 17-
and 23-yr-old healthy individuals who died in traffic
accidents. Samples were kindly donated by Dr. Luis
Santamaria (Autonomous University of Madrid).
Neoplastic tissues were obtained through radical
prostatectomy (n¼ 30) or transurethral resection of
the prostate (TURP, n¼10) in the University Hospi-
tal Rotterdam (The Netherlands). From the TURPs,
four prostates were obtained frompatients whowere
subjected to antiandrogenic therapy and six were
obtained from untreated patients. Most of the speci-
mens from radical prostatectomy (RPs) (n¼25) and
all the samples from TURPs were fixed in 10%
buffered formalin and paraffin embedded. Tumor
grade was determined according toGleason’s system
[17]. Gleason sum scores (GSS) assigned to the
patients were 4 (n¼2), 5 (n¼1), 6 (n¼ 6), 7 (n¼5),
8 (n¼ 5), 9 (n¼4), and10 (n¼2) for theRPs.Gleason
sum score for the TURPs ranged from 7 to 10. Five
samples from RPs were frozen at 808C for protein
extraction. All tissue procurement protocols were
approved by the relevant institutional committees.
Prostatic Tumor Cell Lines and Culture Conditions
Androgen-independentDU145 andPC-3 cell lines
and androgen-dependent LNCaP and PC-346C cell
lines were studied. DU 145, PC-3, and LNCaP were
established from PC metastasis [18–20]. The PC-
346C line was derived from the human prostate
tumor xenograftmodel PC-346 [21] and corresponds
to a primary tumor. This cell line was donated by the
Department of Experimental Urology of the Erasmus
University (Rotterdam, The Netherlands). DU 145,
PC-3, and LNCaP were obtained from the American
Type Culture Collection (Manassas, VA).
Cell lines were cultured in 5%CO2 at 378C. All cell
lines but PC-346Cwere grown inRPMI1640medium
with Glutamax-I (Gibco BRL, Life Technologies,
Paisley, UK) supplemented with 7.5% fetal calf
serum (FCS) (Bodinco B.V., Alkmaar, The Nether-
lands), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (Gibco). PC-346C was grown in DMEM/F12
with L-glutamine (Biowhittaker Europe, Verviers,
Belgium) supplemented with 2% FCS, penicillin,
streptomycin, 1010 M synthetic androgen R1881
(NEN Life Science, Zaventem, Belgium) and various
GFs as previously described [22].
Androgen-deprivation experiments were carried
out with the androgen-dependent LNCaP cell
line. Cells were cultured in RPMI 1640 medium
supplemented with antibiotics and dextran-char-
coal–stripped FCS (FCS-DCC), for 3, 7, or 14 d. A
time-point experimentwas also included to examine
the re-expression of the target molecules after
androgen-replacement. Thus, some LNCaP cells
were cultured for 7 d with FCS-DCC–supplemented
medium, and subsequently with FCS-supplemented
medium for 3 d. These cells cultured in hormone-
replaced conditions were called LNCaP 7þ3. LNCaP
cells cultured in FCS-DCCmedium stopped prolifer-
ating, thus indicating the effectiveness of androgen
ablation in themedium. To verify further the success
of androgen ablation, protein levels of androgen
receptor (AR) were analyzed by Western blotting. As
expected, the intensity of the androgen receptor–
specific 110 kDa band decreased in FCS-DCC cul-
tured cells compared to controls (result not shown).
This observation coincides with others previously
reported for LNCaP [6] and other androgen-depen-
dent prostatic experimental models [23,24].
Cellswereharvestedby trypsinization. Pelletswere
either stored at808C for RNA isolation and protein
extraction or processed for immunohistochemistry.
In the latter case, cells were fixed in Bouin’s fluid for
2 h at 48C, and then mixed with 1–2% agarose at
558C. Once solidified, agarose blocks were paraffin-
embedded.
PC-310 Human Prostate Tumor Xenograft Model
The PC-310 model was established from a human
primary PC at the Department of Experimental
Urology in Erasmus University [21]. Small pieces of
tumor were subcutaneously implanted in NMRI
athymic nude mice (Harlan Company, Horst, The
Netherlands). Mice were androgen-supplemented
through Silastic implants containing testosterone
(Sigma, St. Louis, MO). Castration was performed
and the mice were sacrificed at day 0, 2, 5, 7, 14,
and 21 postcastration [25]. Androgen-withdrawal
success was tested by measuring the level of the
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androgen-dependent prostatic specific antigen (PSA)
in the sera of the tumor-bearing mice. The prostatic
specific antigen concentration in the control (non-
castrated) host mice was approximately 200 ng/mL,
but it dropped rapidly postcastration andwasmaint-
ained around zero after 14 d [25].
Prostatic tumors were either fixed in 4% buffered
formalin and paraffin-embedded for immunohisto-
chemical detection or snap-frozen in liquid nitrogen
and stored at 808C for Western blot analysis.
Antibodies and Peptides
Immunoreactivity for AMwas demonstrated using
apolyclonal antiserumraised in rabbit to the amidat-
ed AM22–52 synthetic human sequence. The specifi-
city of this antiserum has been previously assessed
[26]. Optimal dilution determined for immunohis-
tochemistry was 1:1000 (for clinical and xenograft
tissues) and 1:4000 (for cell lines). In Western blot
analysis, the anti–AM antibody was applied at a
1:2000 dilution for tissues and at a 1:4000 dilution
for cell lines. To detect PHM/PAM immunoreactiv-
ity,weused amonoclonal antibody (cloneG8) raised
against the bovine PHM region (bPAM288–310). This
antiserum recognizes human PAM [14] and was
applied at a 1:1000 dilution for immunohistochem-
istry and at a 1:1500 (tissue extracts) or a 1:3000 (cell
extracts) dilution for Western blotting. Antigenic
peptides, amidated-AM22–52 and bPAM288–310, were
used for the absorption controls, at a concentration
of 10 mM.
Immunohistochemistry
Sections 4 mm thick were obtained from the
paraffin-embedded tissues and cells and placed on
Vectabond (Vector Laboratories, Burlingame, CA)
pretreated slides. To detect AM in the clinical and
xenograft tissues, we used a previously described
protocol [25]. For evaluating AM and PHM/PAM
expression in the cell lines, we applied a detection
method based on the EnVisionTMþ System (Dako,
Carpinteria, CA). Cell slides were deparaffinized and
rehydrated, and endogenous peroxidase was inhib-
ited in a 3% H2O2 solution in deionized H2O for
10 min. Microwave pretreatment was applied for
antigen retrieval [25]. Slides were blocked with
normal goat serum (1:20) at room temperature for
30 min and incubated overnight with the specific
antiserum at 48C. Sections were incubated at room
temperature for 30 min with horseradish peroxidase
labeled polymer conjugated to goat antirabbit
or antimouse (according to the primary antibody
applied) immunoglobulins (EnVision). Peroxidase
activity was detected with 3-30-diaminobenzidine.
Slides were counterstained with Harris’ hematoxy-
lin, dehydrated and embedded inDPX. Pictures were
taken with a Nikon Eclipse E800Mmicroscope.
For absorption controls, optimal dilutions of prim-
ary antisera preincubated at 48C with the corre-
sponding antigen at 10 mM were applied onto the
slides instead of the primary antiserum.
Protein Extraction and Western Blot
Prostatic tissues were crushed in a metal cylinder
cooled down at 808C, and cell pellets were kept on
ice for 5 min. Then, lysis buffer [25] containing a
cocktail of protease inhibitors (CompleteTM; Roche
Diagnostics, Penzberg, Germany) was added to both
types of samples. After centrifugation (12 000 g, at
48C, 10 min), supernatants were recovered and the
protein concentration was spectrophotometrically
measured by the binciconic acid method (BCATM
protein assay kit; Pierce, Rockford, IL).
For AM detection, each sample was transferred to
10–20% tricine SDS-PAGE gels (Invitrogen, Carsl-
bad, CA). Bovine adrenal medulla extracts were
loaded as positive control [10]. For PHM/PAM
analysis the samples, and H69 small cell lung
carcinoma (SCLC) cell line as control [27], were
loaded in NuPAGE 3–8% tris-acetate SDS-PAGE gels
(Invitrogen). Cells or tissue samples consisted of 30
or 50 mg of protein extracts, respectively. Unstained
Mark12TMWideRangeProtein Standard (Invitrogen)
wasused asmolecularweight standard. Proteinswere
electrophoretically separated, and blotted as pre-
viously described [13] for the AM detection.
Blots were blocked overnight at 48C with 5% milk
in phosphate buffer saline (PBS; pH 7.5). Anti–AMor
anti–PHM antisera diluted in PBS/milk was added
subsequently, andmembraneswere incubated for1h
on an orbital shaker at room temperature. Mem-
branes were rinsed with 0.1% Tween-20 (Fluka
Chemika, Switzerland) in PBS. An incubation with
horseradish peroxidase–conjugated antirabbit (for
AM) or antimouse (for PHM/PAM) secondary anti-
bodies (Amersham, Life Science, UK) diluted 1:5000
or 1:4000 respectively in PBS/milk was performed for
1 h at room temperature. Membranes were rinsed
with PBS/Tween and Western blotting luminol
reagent (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) was added for 1min. Blots were then exposed to
high performance chemiluminiscence film (Hyper-
filmTMECLTM;Amersham). Finally,membraneswere
stained with Serva Blue R (Serva Electrophoresis,
Heidelberg, Germany) in order to assess the uniform
loading of protein samples.
Cell RNA Isolation and RT-PCR
TotalRNAfromprostatic cell sampleswasobtained
with the UltraspecTM RNA Kit (Biotecx, S. Loop E.
Houston, TX), following themanufacturer’s instruc-
tions. The RNA concentration was spectrophotome-
trically determined.
RNA retrotranscription was performed with M-
MLV reverse transcriptase (Invitrogen). PCRwas per-
formed by using Taq DNA polymerase (Invitrogen)
in a GeneAmp PCR System 2400 (Perkin Elmer,
Foster City, CA). Primers for human preproAM cDNA
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amplification were designed to allow the elongation
of intron 3 in the processed mRNA, if present. These
primers for preproAM (Genbank: D14874) were: 50-
AAGAAGTGGAATAAGTGGGCT-30 (sense, nucleo-
tides 250–270) and 50-TGTGAACTGGTAGATCTG-
GT-30 (antisense, nucleotides 521–540). In the case
of human PAM, selected primers amplify the most
variable region among all described PAM transcrip
variants, which includes the linker region A. Primers
for PAM (Genbank: M37721) amplification were: 50-
AGAACCATACCACCAGAGG-30 (sense, nucleotides
1203–1221) and 50-GTCTTCTTCAATTGGTCCG-30
(antisense, nucleotides 1841–1859). PCR products
were run in 1% agarose gels and scanned with
Gelprinter SuperII (Tecnologı´a para Diagno´stico e
Investigacio´n, Madrid, Spain) equipped with the
Windows Software ScionImage.
Analysis of Amplified cDNA by Cloning and Sequencing
All the PCR products were purified using Gene-
clean II Kit (Bio101, Carslbad, CA) and cloned into
PCTM II vectorof theTACloningkit (Invitrogen). The
correct size of the cloned inserts was confirmed by
digesting the plasmidswith Sac I and EcoRV for PAM,
and with EcoR I for AM (all enzymes from New
England BioLabs, Norwalk, CN). Inserts were
sequenced using an Abi Prism 377 DNA sequencer
(Applied Biosystems, Foster City, CA). Three differ-
ent clones were sequenced for each PCR band to
ensure the accuracy of the results.
Northern Blot Analysis
Northernblot analysiswas performed for preproAM
mRNA detection in PC cell lines. Ten micrograms
of total RNA were loaded in 1% agarose 2.2 M
formaldehyde gels. Total RNA from H157 SCLC cell
line was used as positive control [27]. The procedure
used and the characterization of the human pre-
proAM cDNA probe applied have been described
previously [28]. Relative preproAM mRNA levels were
normalized with the S9 ribosomal protein mRNA.
Autoradiograms were scanned with a Sharp JX-325
apparatus and densitometric analysis wasmadewith
the Software ImageMaster 1D (Amersham).
RESULTS
PreproAM Gene Expression in Clinical
and Experimental Human Prostatic Carcinoma
Immunohistochemistry for AM
Clinical and experimental PC exhibited cytoplas-
matic staining for AM (Figure 1A–H). Normal
prostate showed immunostaining for AM in the
epithelium of the glands and ducts (Figure 1A), as
previously described [13]. Glands in the peripheral,
central, transition, and periurethral areas were
similarly stained. A heterogeneous pattern of inten-
sity of staining was observed in normal glands and
ducts, which was independent of the zone of the
prostate. Thus, glands with different intensity of
staining could be observed in the same zone of the
prostate (result not shown).
In PC clinical samples, 34 of 35 specimens showed
immunoreactivity for AM. In RPs, AM immunostain-
ingwasobserved ineitherwell,moderately, orpoorly
differentiated neoplastic glands (Figure 1B–F). How-
ever, the intensity of the staining was heterogenous
and both strong and faint immunoreactivity was
found, independently of the tumor differentiation
grade and GSS (result not shown). Absorption cont-
rols demonstrated the specificity of the immunola-
beling (Figure 1E,F). Semiquantification of AM was
not performed, given the variability of the staining
intensity and the apparent lack of association be-
tween AM immunoreactivity and GSS.
We also analyzed TURPs samples from patients
treated with antiandrogenic therapy and untreated
patients. Results in TURPs were similar to those
observed for RPs (Figure 1G). All the samples were
immunoreactive for AM, with no clear association
between GSS or tumor differentiation grade and
intensity of AM staining. Antiandrogenic therapy
did not change the pattern of immunoreactivity
compared to untreated patients (Figure 1G).
In the prostate cancer, model PC-310 xenografted
into nude mice with normal levels of testosterone
(Figure 1H), AM immunoreactivity was found in the
neoplastic epithelium of all the animals studied. To
determine if AM expression was androgen depen-
dent, a group of mice were castrated and AM
expressionwas analyzed by immunohistochemistry.
After castration, tumor cells were positive for AM in
all the mice analyzed, and the pattern and intensity
of AM staining remained as for those of control mice
(noncastrated). PC-310 tumors were positive for AM
staining even 21 d postcastration (data not shown).
These results strongly suggest that AM expression in
prostate cancer is independentof circulating levels of
androgens.
PC cell lines (DU 145, PC-3, LNCaP, and PC-346C)
grown in the presence of androgens showed im-
munoreactivity for AM (representative examples
are shown in Figure 2). To determine whether
expression of AM was mediated by androgens in
in vitro settings, we cultured the androgen-depen-
dent LNCaP cell line with an androgen-depleted
medium. Expression of AMdid not change in LNCaP
cells cultured inandrogen-free conditions (evenafter
14 d) compared to controls (Figure 2). This result
supports the in vivo data on the androgen indepen-
dence of AM expression.
Western blotting for AM
Protein extracts from PC samples (five clinical
specimens, the four cell lines, and the PC-310model)
and from adrenal medulla (positive control) showed
two AM-immunoreactive bands with approximate
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molecular weights of 13 and 22 kDa (Figure 3). In
most caseswealsodetectedanother immunoreactive
band of 15 kDa (Figure 3). None of the prostatic
samples exhibited the 6 kDa band corresponding to
the fully processed AM,whereas the adrenalmedulla
did (Figure 3A). All bands were absent in the
adsorption controls (figure not shown).
LNCaP cells cultured in hormone-depleted or in
hormone-replaced media, and PC-310 tumors kept
in castrated mice, showed the same pattern of AM-
immunoreactive bands (Figure 3B). The intensity of
the bands obtained for both models remained un-
changed throughout the experimental time-points
(Figure 3B). Therefore, Western blot analysis con-
firmed our previous immunohistochemical results.
RT-PCR for preproAM mRNA in PC
cell lines and sequencing of cDNAs
In prostatic cell lines and in H157 SCLC cell line
(positive control), a strong band with the expected
size for the PCR amplified preproAM cDNA (291 bp)
Figure 1. Sections of clinical PC and experimental PC models
immunostained for AM (A–H). In the normal prostate, epithelial
cells of the glands (A) and ducts are positive for AM. The staining is
stronger in the basal area of the cells in many glands. In clinical
specimens, AM immunostaining is found in the cytoplasm of tumor
cells in well (B), moderately (C), or poorly (D) differentiated neoplastic
glands and also in normal glands (arrow in B). AM adsorption control
is shown in F (consecutive section to E). TURPs from patients treated
with antiandrogenic therapy also show AM-immunostaining in
tumoral glands (G). No differences in the pattern or intensity of
staining is observed between samples from patients treated and
untreated. PC-310 tumor xenografted into nude mice also shows
AM–immunolabeling (H), which was independent of levels of
circulating testosterone. Gleason sum scores: B¼ 8; C¼ 8; D¼ 9;
E/F¼ 4; G¼ 10. Bar size corresponds to 25 mm.
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was detected (Figure 4A). Two other fainter bands of
441 and 524 bp were observed in all the samples.
These three cDNAs were also found for LNCaP cells
grown in hormone-depleted or -replaced media
(Figure 4A). Water control did not render any band
(data not shown).
All amplified cDNAs were cloned and sequenced.
The 291 bp band corresponded to the preproAM
cDNA that was described previously. Sequencing of
the 524-bp cDNA showed that this transcript con-
tained the 291-bp bandplus the third intron (233 bp)
of the preproAM gene. Thus, the 524-bp band was
identical to that reported for a recently identified
alternatively-spliced preproAM gene–derived mRNA
[29]. Sequencing of the 441-bp cDNA showed that
this form corresponded to the 291-bp band plus
primer concatemers and, therefore, it did not re-
present any alternatively spliced mRNA.
Northern blotting for preproAM mRNA in PC cell lines
ByNorthern blot analysis, cell lines showed a band
of approximately 1.4 kb, the expected size for the
preproAMmRNA (Figure 4B). The androgen-indepen-
dent cell lineDU145 exhibited a stronger signal than
the androgen-dependent cell line LNCaP. These
latter cells cultured in hormone-deficient medium
up to 14 d produced a similar amount of preproAM
mRNA to that of cells cultured in androgen-replaced
medium (Figure 4B). Relative preproAM mRNA levels
were normalized to those of the ribosomal protein S9
(Figure 4C). Normalization showed no variation in
preproAM mRNA levels during the androgen-with-
drawal experiment. This experiment shows that lack
of androgens does not alter AM mRNA levels in the
androgen-dependent LNCaP cell line.
Figure 2. PC cell lines immunostained for AM (left panel) or PAM
(right panel). LNCaP cells cultured for 7 d in absence of androgens
show similar staining for AM (C) and PAM (D) as do control cells (A
and B, respectively). PC-346C cells show AM (E) and PAM (F)
immunostaining. Similarly, DU 145 cells are immunostained by AM
(G) and PAM (H). Experiments were performed in triplicate. Bar size
corresponds to 25 mm.
Figure 3. Western blotting for AM. (A) Three AM–immunoreac-
tive bands different of mature AM can be found in clinical PCs and
cell lines as well as in a positive control (adrenal medulla). (B) PC-310
and LNCaP models exhibit the same band pattern in every androgen-
depletion time-point. Number of androgen-deprivation days is
indicated above each lane. 7þ3 means that after 7 d of culture
in androgen-depleted medium, the cells were cultured for 3 d in
androgen-containing medium. Experiments were performed in
triplicate.
Figure 4. (A) RT-PCR for preproAM mRNA detection in PC cell
lines and in positive control (H157). D.L., 100 bp DNA ladder. (B)
Northern blot for preproAM mRNA detection in the same samples
studied in (A). DU-145 shows the strongest signal. LNCaP cells
cultured in androgen depleted medium at different time points show
the same intensity of AM mRNA expression. (C) Loading controls for
the Northern blot. The similar intensities of the 28S (for the different
cell lines) and 9S bands (for the androgen-removal experiment in
LNCaP cells) show that the amount of mRNA loaded was similar in
the wells. Three replicates of the experiment were performed.
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PAM Gene Expression in PC Cell Lines
Immunohistochemistry for PHM/PAM
Expression of PAM in the normal prostate and PC
was previously described by our group [14]. All
prostatic cell lines studied showed PHM/PAM immu-
noreactivity (representative examples are shown in
Figure 2). PHM/PAM staining was positive for the
androgen-dependent LNCaP and PC-346C cells and
the androgen-independent DU 145 or PC-3 cells,
although the latter ones tended to have stronger
staining. LNCaP cells cultured in hormone-depleted
or hormone-replacedmedia showed similar staining
for PAM (Figure 2). Adsorption controls lacked
immunostaining (figure not shown).
Western blot for PHM/PAM
Proteins immunoreactive for PHM/PAM with
estimated molecular weights ranging from 34 to
105 kDawere detected in all the samples (Figure 5A).
The pattern and intensity of the PHM/PAM-immu-
noreactive bands were not identical in all the cell
lines, but a 50 kDa band was the most intense in all
cases. Band intensities were fainter for the androgen-
dependent cell lines LNCaP and PC-346C than
for the androgen-independent DU 145 and PC-3
(Figure5A).Almostallbandswerealsodetected inthe
positive control, the H69 SCLC cell line (Figure 5A).
The PHM/PAM-immunoreactive bands were consid-
ered specific, because all the signals were abrogated
in the adsorption controls (data not shown).
LNCaP cells also showed PHM/PAM immunoreac-
tivity after hormone depletion (Figure 5A). In fact,
the intensity of the bands increased after androgen
deprivation, being highest 14 d after androgen
removal. However, after androgen replacement, the
intensity of the bands did not reach the initial levels
of expression (Figure 5A).
RT-PCR for PAM and sequencing of cDNAs
Four cDNAs (336, 390, 519, and 657 bp) were
amplified from all the cell lines tested (Figure 5B).
The pattern of bands found for LNCaP was not
altered after androgen withdrawal or androgen
replacement (Figure 5B).
The PCR bands of 336, 390, and 657 bp correspond
to the expected sizes for hPAM-B, hPAM-C, and
hPAM-A, respectively. To corroborate further the
identities of these bands, the amplified cDNA was
cloned, purified, and sequenced. Thus, 657- and
336-bp cDNAs are coincident with the hPAM-A
and hPAM-B sequences, respectively, described by
Glauder [30] and the 390-bp bandwithVos’ hPAM-C
[31]. The 519-bp band had not been previously
described. Sequencing of three different clones
revealed the existence of a novel PAM gene tran-
script that was similar to hPAM-A (Figure 6) but
lacked the last 138 bp (nucleotides 1534 to 1671,
Genbank: M37721) of the exon A, codifying for the
region A (a linker zone between PHM and PAL
enzymatic domains). The splicingphenomenon that
renders this new PAM mRNA transcript occurs
between a GT sequence in exon A (nt 1534) and an
AGlocated at the endof the intronpreceding thePAL
domain. Following the current nomenclature for the
PAM proteins, we have called this novel transcript
hPAM-E (Figure 6). hPAM-E maintains the transla-
tional reading frame and would produce a protein
with 46 aminoacids less than hPAM-A. Besides, three
pointmutationswere found in all sequenced 519 bp-
band clones, the three of them belonging to exon A:
E402E (GAA!GAG), T410H (TAT!CAT), and
R448G (AGG!GGG). The first change of nucleotide
described is a silentmutation, whereas the other two
would lead to an aminoacid change in the translated
protein.
DISCUSSION
In the present work we demonstrate that most of
the studied PCclinical samples and all the PCmodels
show AM-like immunolabelling, independently of
the tumor grade, GSS, and androgen levels. The im-
munoreactive bands detected in PC protein extracts
by Western blot (13, 15, and 22 kDa) have also been
described in the positive control (adrenal medulla)
and are specific, as demonstrated by adsorption
controls. These bands probably correspond to the
preproAM and intermediate processing–derived pep-
tides, as suggested by others [9]. The fact that human
PC samples lack fully processedAMbut express other
AM-immunoreactive peptides could have two possi-
ble explanations. Many authors have suggested that
mature AM (corresponding to the 6 kDaband)would
be rapidly processed from the preproAM form and
constitutively secreted into the media. This hypoth-
esis is supported by the observation of ahigh amount
of mature 6 kDa AM in the secreted medium of cells
where endogenous mature AM is almost absent
Figure 5. (A) Western blot for PHM/PAM in PC cell lines and in
positive control (H69). Several immunoreactive bands are detected.
(B) RT-PCR for PAM mRNA detection in the same cases showed in
(A). The 519 bp band corresponds to the novel isoform that we have
called hPAM-E. D.L., 100 bp DNA ladder. Experiments were
performed in triplicate.
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[32,33]. This is also true for the human prostate PC-3
cells [16]. This finding correlates with the very low
peptide/mRNA ratio found in many cell systems,
which indicates a rapid secretion of AM [34,35]. The
second possibility, which has also been suggested by
several authors, claims that those larger peptides are
secreted and have a physiological relevance. This
last option is based on several observations: (1)
Western blot analysis of extracts obtained from
specific areas of some organs (i.e., rat prostate [13]
and brain [36]) only show AM precursors while in
other zonesof thoseorgans,matureAMis also found;
Figure 6. Schematic representation for RT-PCR and sequencing
results. (A) Amplified region by RT-PCR. The exons encoding for each
protein region are named and drawn to scale in thick lines. Note that
for PAM E, the splicing phenomenon occurs among an intermediary
sequence inside exon A and the first exon coding for PAL (PAL1). (B)
The complete amplified nucleotide sequence for PAM E is included.
Underlined nucleotides indicate primer localization. Highlighted
nucleotides are changed with respect to previously published sequ-
ences. Dotted gaps indicate the region where the novel alternative
splicing occurs. (C) PAM proteins with the hypothetical structure of
the newly described PAM E. Signal peptide and citoplasmatic domain
(CD) are included. Localization of paired basic amino acid residues
representing potential cleavage sites (arrow heads) are indicated only
in PAM D and PAM E proteins.
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(2) AM-immunoreactive molecules larger than the
fully processed AM are secreted in certain systems,
like plasma [37], milk [38], and culture-conditioned
mediaof certain cancer cell lines [9]; and (3)finally, it
has also been described that either mature AM or
precursors can be secreted by astrocytes depending
on the presence of cytokines in the culture medium
[39].
Northern blot analysis has demonstrated that all
the PC cell lines studied produce the preproAM
mRNA. However, PCR amplification has shown that
together with the classical mRNA, another recently
identified alternatively-spliced mRNA [29] derived
from preproAM gene is also expressed. This mRNA
(that has been detected by in situ hybridization in
normal neuroendocrine prostatic cells) retains an
intron that includes an early stop codon and thus,
encodes for a precursor containing PAMPbutnotAM
[29]. Our previous work shows that PAMP immuno-
reactivity in prostate is detected in neuroendocrine
cells but not in the non-neuroendocrine cell popula-
tion [13,14]. The presence of mRNA encoding
specifically for PAMP in the PC cell lines we have
studied is an unexpected finding and needs further
clarification, since none of these cell lines exhibit
neuroendocrine phenotype under normal culture
conditions.
The variety of PAMmRNAs and proteins found in
the prostaticmaterial is likely related to the presence
of different substrates susceptible to amidation. We
previously reported that PAM is expressed in PC
neuroendocrine and non-neuroendocrine neoplas-
tic cells [14].Our present study shows the presence of
different PAM mRNAs and PHM/PAM proteins in
extracts of the non-neuroendocrine cells DU 145,
PC-3, LNCaP, and PC-346C. Alternative splicing of
the PAM gene renders several mRNA forms [40].
There are five human PAM transcripts described
in the study so far: hPAM-A, hPAM-B, hPAM-C,
hPAM-D, and PAM-15 [30,31,41]. They differ in the
presence or absence of the linker regions between
PHM and PAL sequences (exons A and/or C) and/or
the transmembrane domain (Figure 6). We have
found that neoplastic prostate cell lines express
hPAM-A, hPAM-B, and hPAM-C mRNA. However,
the657-bpbandcould also represent PAM-15mRNA,
because the two proteins do not differ in the region
amplified by our specific PAM primers.
Together with these known PAMmRNAs, we have
identified a new variant that has probably been
originated by mRNA alternative splicing. We have
called it hPAM-E, and differs from the other de-
scribed forms in the linker region between PHM and
PAL, known as region A. The region A is codified by a
single exon in chromosome 5. This implies that the
alternative splicing found inhPAM-Eoccurs between
the end of the intron preceding the PAL domain and
an internal sequence of exon A. Indeed, the two
initial nucleotides in the missing region of the exon
A are GT. A protein translated from hPAM-E would
lack 46 aminoacids from theCOOH–terminus of the
regionA,which is a 107-aminoacid sequence located
between the enzymatic domains PHM and PAL.
hPAM-E protein would maintain the paired basic
residues (KK) necessary for the endoproteolytic
cleavage that separates PHMfromPAL. The existence
of a protein with such amodified linker region could
have importantphysiological implications. RegionA
exhibits pH-dependent conformational changes
that determine whether the dibasic aminoacids are
accessible to endoproteolysis [42]. Therefore, struc-
tural changes in hPAM-E could involve a way of
regulating the proteolytic separation of the PAM
enzymatic domains through the secretory pathway.
Besides, it is worth noting that changes in tyrosine
and histidines in region A have been described as
important for a rapid trans-Golgi network traffic and
for Cu-ion binding, necessary in the PHM catalytic
reaction, respectively [43,44]. The relevance of the
novel alternative splicing mechanism we hypothe-
size here, as well as the significance of the two
aminoacid changes, should be further studied.
Translation of human PAM mRNAs renders a
bifunctional enzyme (containing PHM and PAL acti-
vities). They are all transmembrane precursors,
except for PAM-15, which is soluble. Through
endoproteolitic cleavage, PAM can produce mono-
functional enzymes (PHM or PAL) [12]. By Western
blot analysis, we have detected several PHM/PAM–
immunoreactive proteins in PCand inH69 SCLCcell
lines. A PAM bifunctional enzyme should have a
minimal relative molecular mass of 75 kDa [45]. In
our case, the band of 105 kDa could correspond to
any of the bifunctional PAM (including PHM and
PAL domains), most likely to hPAM-A [41]. Bands
below 75 kDa probably correspond to monofunc-
tional PHM proteins. These PHM molecules may be
biologically active. It has beendemonstrated that the
smallest PHM fragmentmaintaining enzymatic acti-
vity weighs 34 kDa [45]. This hypothesis is further
supported by the finding that DU 145, PC-3, and
LNCaP cells exhibit PHM activity [15].
We have found that PC samples show AM and
PHM/PAM immunostaining independently of being
androgen-dependent (PC-310 xenograft model, PC-
346C and LNCaP cells) or -independent (DU 145 and
PC-3 cell lines). AM–related peptides are produced
by neoplasic cells in the PC-310 model, even after
host mice castration. In addition, LNCaP expresses
the preproAM gene after steroid hormone-depletion.
It has beenobserved that preproAMmRNAexpression
in rat ventral prostate is downregulated after castra-
tion [46]. However, our present results show that this
does not seem to be the case for the human prostate.
There exist important ontogenic and biological
differences between human and rat prostate. The
divergence is larger in the case of rat prostatic ventral
lobes, whose embryological origin is different from
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that of the human prostate [47]. Although all the rat
lobes express androgen receptor, a distinct androgen
regulation of certain proteins occurs in each parti-
cular type of lobe. For example, the expression of
metalloproteases [48] or adhesionmolecules, such as
C-CAM [49] is controlled by androgens in the rat
ventral prostate, but not in the dorsal prostate.
Therefore, the fact that AM expression is androgen-
dependent in the ventral lobes of the rat prostate
does not imply a similar regulation in the dorsolat-
eral lobes or in the human prostate.
In a previous work we reported that androgen-
independent PCxenograftmodels showeda stronger
PHM/PAM-immunostaining than androgen-depen-
dent tumors [14]. Consistently with those data, our
Western blot analysis shows that androgen-indepen-
dent DU 145 and PC-3 cells havemore intense PHM/
PAM-immunoreactive bands than androgen-depen-
dent (LNCaP or PC-346C) cell lines. Moreover, the
intensity of the bands derived from LNCaP extracts
seem to increase after hormone deprivation, show-
ing that androgen removal induces the expression of
PAM protein. This leads most likely to an increase in
the amidation rate (and therefore, bioactivation) of
peptides in androgen-independent conditions.
Active amidated peptides can have different roles in
prostate cancer cells. Some peptides promote pro-
liferation, whereas others exert cell growth inhibi-
tion. The final effect will probably depend on the
balance of both types of peptides. Regarding AM, we
have recently shown that cells overexpressing this
peptidehavedecreasedcellproliferationrates invitro
and tumorigenicity in vivo [16].
In summary, we demonstrate in the present work
that the expression of preproAM and the amidating
enzyme PAM is androgen-independent in PC. We
also show that preproAM is widely expressed in PC,
independently of the tumor grade, and levels of
circulating androgens. Thus, AM-related peptides
and especially PHM/PAM,whose expression tends to
increase in hormone-deficient conditions, could
play a role in the local control of prostate tumor
growth after long-term androgen-withdrawal ther-
apy. Finally, we report the presence in PC of a novel
transcript derived from thehumanPAMgene,which
lacks a part of exon A region, i.e., hPAM-E.
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